Novel method and device for treatment of exercise induced pulmonary hemorrhage in horses

• US 20040053938A1
• Filed: 07/16/2003
• Published: 03/18/2004
• Est. Priority Date: 08/01/2002
• Status: Abandoned Application

• Current Assignee: Calvert R. Bratton, Thomas Tobin
• Original Assignee: Calvert R. Bratton, Thomas Tobin
• Inventors: Bratton, Calvert R., Tobin, Thomas
• Application Number:
  US10/466,803
• Publication Number:
  US 20040053938A1
• Time in Patent Office: Days
• US Class Current: 514/252.16
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A device and method are provided for convenient, patient compliant inhalation therapy of equine species. The device can be used to deliver any drug or other pharmaceutical agent which can be adapted for inhalation directly into the nasal passages of a horse and thereby provide inhalation therapy with minimal discomfort. The device can be used to treat any of a number of conditions including, EIPH, infections and allergies, e.g., asthma or heaves. In one embodiment, the invention provides a method for the treatment or prevention of EIPH, utilizing a composition adapted for inhalant therapy comprised of sildenafil citrate alone or in combination other agents.

Claims

1. A method for the treatment of exercise induced pulmonary hemorrhage (EIPH) in an equine, comprising administering to the equine a therapeutic amount of a composition comprised of sildenafil citrate or a pharmaceutically acceptable derivative thereof.

2. The method of claim 1, wherein the therapeutic amount comprises from between about 0.01 mg/kg and about 10 mg/kg of sildenafil citrate.

3. The method of claim 2, wherein the therapeutic amount comprises about 2.0 mg/kg of sildenafil citrate.

4. The method of claim 1, wherein the composition comprising sildenafil citrate is adapted for localized delivery into the lungs of the subject equine via nebulization, the composition being admixed with suitable liquid and administered to the equine via nebulization into an airflow stream at a rate of between about 50 to about 200 parts per million (ppm) but especially from about 80 to about 100 ppm.

5. The method of claim 4, wherein the flow rate of the air stream is between about 1 and about 4 liters per minute, but is especially between about 2 and about 3 liters per minute.

6. The method of claim 4, wherein the suitable liquid is water.

7. The method of claim 4, wherein the suitable liquid is DMSO.

8. The method of claim 1, wherein the composition further comprises DMSO.

9. The method of claim 1, wherein the composition is administered to the equine via nebulization and inhalation into the equine'"'"'s lungs.

10. The method of claim 9, wherein the composition further comprises a therapeutic amount of a second phosphodiesterase inhibitor.

11. The method of claim 10, wherein the phosphodiesterase inhibitor is selected from the group consisting of zapranist, MY5445, dipryidamole and mixtures thereof.

12. The method of claim 1, wherein the composition further comprises a therapeutic amount of a nitric oxide precursor.

13. The method of claim 12, wherein the nitric oxide precursor is L-arginine.

14. The method of claim 1, wherein the composition further comprises a therapeutic amount of a nitric oxide donor.

15. The method of claim 14, wherein the nitric oxide donor is selected from the group consisting of nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, sodium nitroprusside, molsidomine, linsidomine chlorhydrate, S-nitro-N-acetyl-d, 1-penicillamine, S-nitroso-N-cysteine, S-nitro-N-glutathine, diazenium diolates, and mixtures thereof.

16. The method of claim 1, wherein the composition further comprises a therapeutic amount of a nitric oxide analog.

17. The method of claim 16, wherein the nitric oxide analog is selected from the group consisting of nitroglycerin, nitroprusside, Sin1 and mixtures thereof.

18. The method of claim 1, wherein the composition further comprises a therapeutic amount of a suitable iron chelating agent.

19. The method of claim 18, wherein the suitable iron chelating agent is des-ferox amine.

20. A method for the prevention of exercise induced pulmonary hemorrhage (EIPH) in an equine, comprising administering to the equine a prophylactic amount of a composition comprised of sildenafil citrate or a pharmaceutically acceptable derivative thereof.

21. The method of claim 20, wherein the prophylactic amount comprises from between about 0.01 mg/kg and about 10 mg/kg of sildenafil citrate.

22. The method of claim 21, wherein the propyhlactic amount comprises about 2.0 mg/kg of sildenafil citrate.

23. The method of claim 20, wherein the composition comprising sildenafil citrate is adapted for localized delivery into the lungs of the subject equine via nebulization, the composition being admixed with suitable liquid and administered to the equine via nebulization into an airflow stream at a rate of between about 50 to about 200 parts per million (ppm) but especially from about 80 to about 100 ppm.

24. The method of claim 23, wherein the flow rate of the air stream is between about 1 and about 4 liters per minute, but is especially between about 2 and about 3 liters per minute.

25. The method of claim 23, wherein the suitable liquid is water.

26. The method of claim 23, wherein the suitable liquid is DMSO.

27. The method of claim 20, wherein the composition further comprises DMSO.

28. The method of claim 20, wherein the composition is administered to the equine via nebulization and inhalation into the equine'"'"'s lungs.

29. The method of claim 28, wherein the composition further comprises a prophylactic amount of a second phosphodiesterase inhibitor.

30. The method of claim 29, wherein the phosphodiesterase inhibitor is selected from the group consisting of zapranist, MY5445, dipryidamole and mixtures thereof.

31. The method of claim 20, wherein the composition further comprises a prophylactic amount of a nitric oxide precursor.

32. The method of claim 31, wherein the nitric oxide precursor is L-arginine.

33. The method of claim 20, wherein the composition further comprises a prophylactic amount of a nitric oxide donor.

34. The method of claim 33, wherein the nitric oxide donor is selected from the group consisting of nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, sodium nitroprusside, molsidomine, linsidomine chlorhydrate, S-nitro-N-acetyl-d, 1-penicillamine, S-nitroso-N-cysteine, S-nitro-N-glutathine, diazenium diolates, and mixtures thereof.

35. The method of claim 20, wherein the composition further comprises a prophylactic amount of a nitric oxide analog.

36. The method of claim 35, wherein the nitric oxide analog is selected from the group consisting of nitroglycerin, nitroprusside, Sin-1 and mixtures thereof.

37. The method of claim 20, wherein the composition further comprises a prophylactic amount of a suitable iron chelating agent.

38. The method of claim 37, wherein the suitable iron chelating agent is des-ferox amine.

39. A device for removable attachment to the head of an equine that is adapted to provide inhalation therapy of a preselected agent to the subject equine, the device comprising:

Bilateral elongated delivery tubes, each tube having a proximal end, a distal end and a body there between defining a longitudinal axis, the bilateral elongated delivery tubes being positioned relative to one another such that the body of each tube is substantially parallel along the longitudinal axis;

An inhalator manifold having a proximal end and a distal end;

the distal end of the inhalator manifold being in fluid connection with the proximal ends of the elongated delivery tubes and in fluid communication with a remote drug supply means at the proximal end of the inhalator manifold; and

Attachment means for removable attachment of the device to the head of the subject equine such that the longitudinal axis of each elongated delivery tube is held in a preselected position that is substantially parallel to the bridge of the nose of the subject equine'"'"'s forehead with the distal ends of the bilateral elongated delivery tubes held adjacent the external openings of the nostrils of the subject equine.

40. The device of claim 39, wherein the attachment means is a halter.

41. The device of claim 39, wherein the proximal end of the inhalator manifold is fluidly connected to the drug supply means by an elongated flexible tube.

42. The device of claim 39, wherein the drug supply means further comprises a source for providing air flow at a preselected volume and a nebulizer for introduction of the preselected agent at a predetermined concentration.

43. The device of claim 39, wherein the attachment means provides a removable attachment to a halter.

44. The device of claim 39, wherein the attachment means provides a removable attachment to a bridle.

45. The device of claim 39, wherein the body of each bilateral elongated delivery tube has an adjustment means for adjustment of the length of the body to a preselected distance.

46. The device of claim 45, wherein the adjustment means for each bilateral elongated delivery tube further comprises:

a first segment of the bilateral elongated delivery tube having a distal end with an inside diameter that is sized complimentary to the outside diameter of the proximal end of a second segment such that the proximal end of the second segment is slidably and sealingly engaged with the distal end of the first segment.